CJC 1295 wit DAC 5mg

▎ CJC1295 Wit DAC Struktrɔ

▎ CJC1295 Wit DAC Risach

Wetin na di risach bakgrɔn fɔ CJC1295 Wit DAC?

di aplikeshכn fכ tradishכnal gכt hכmon-rilis כmon (GHRH) fכ tritmεnt de sכmtεm biכs di sכt tεm we i de akshכn. Dis dɔn mek di wan dɛn we de stɔdi bɔt dis dɔn luk fɔ mɔ ɔmon analɔg dɛn we de rilis di ɔmon we de gro fɔ lɔng tɛm fɔ mek di tritmɛnt wok fayn ɛn fɔ mek i izi fɔ du am. Wit pipul dɛm we de tray fɔ gɛt wɛlbɔdi ɛn biuti, pɔblik ɔnlayn pipul dɛm famakɔlɔji dɔn gi di impetus fɔ shɔtkat fɔ ajɔst di mɔsul ɛnhansmɛnt, fɔ ridyus fat, ɛn yɔŋ skin. agens dis bakdrop, sεntetik gכt hכmon analכg dεm lεk CJC1295 Wit DAC dεn dכn atrak atεnshכn. Risach sho se di wan dɛn we de yuz di fɔm de sho se dɛn sabi ɛn gɛt ɛkspiriɛns fɔ yuz am fɔ bɔku tin dɛn, ɛn di rizin dɛn we mek dɛn pik fɔ yuz dɛn kayn tin ya na fɔ lɛ dɛn lɔs dɛn wet, fɔ mek dɛn mɔsul dɛn fayn, fɔ mek dɛn skin yɔŋ, fɔ mek dɛn slip fayn, ɛn fɔ mek wund dɛn wɛl, ɛn ɔda tin dɛn ^[1] . as lכng-aktin gכt hכmon-rilis כmon analכg, di divεlכpmεnt fכ CJC1295 Wit DAC de bays pan dip כndastandin fכ di rεgεdyushכn mεkanism fכ gכt כmon. pan ɔl we bɔku pikin dɛn we nɔ gɛt isol growth ɔmon (GH) kin gɛt gud growth rispɔns to GHRH, di haf layf fɔ GHRH kin shɔt pasmak, we kin mek i nɔ gɛt bɛtɛ tritmɛnt ifɛkt. Fɔ adrɛs dis prɔblɛm, risach pipul dɛn dɔn mek CJC1295 Wit DAC, we na wan GHRH analɔg we de wok fɔ lɔng tɛm. stכdi dεn sho se i inkכrporεt wan fכnshכnal maleimide grup na di C-tεrminus, we de alaw am fכ kכvalεntli biεn to plasma protin dεm lεk sεrum albumin, we de mek i inkrεs in haf layf εn i kin ebul fכ mek di gכt hכmon prodakshכn insay mכtalman fכ mכr dan siks de afta wan administreshכn ^[2].

Wetin na di mεkanism fכ akshכn fכ CJC1295 Wit DAC fכ trit spεshal sik dεm?

Fɔ mek di ɔmon we de mek pɔsin gro: 

CJC1295 wit DAC na pεptida-bεys dכg we kin stimulate di prodyushכn fכ gכt כmon (GH) frכm di pituitary gland ^{[2, 3]} I inkכrporεt wan fכnshכnal maleimide grup na di C-tεrminus, we de alaw am fכ kכvalεntli biεn plasma protin dεm lεk sεrum albumin. dis binding de gi di CJC1295-protein conjugate wan bכku lכng haf-layf εn i de mek i ebul fכ stimulate GH prodakshכn insay mכtalman fכ mכr dan siks de afta wan singl administreshכn. stכdi dεn sho se sכbkutan injεkshכn fכ CJC1295 Wit DAC kin mek wan sכstayn, dכz-dipεndεnt inkrεs pan di lεvεl dεm fכ GH εn insulin-lεk growth fכktכ I (IGF-I) insay hεlty big pipul dεm ^{[2, 3]} Afta wan injεkshכn fכ CJC1295 Wit DAC, di avεrej plasma GH kכnsantreshכn inkrεs bay 2-10 tεm εn i las fכ 6 dez כ lכng, εn di avεrej plasma IGF-I kכnsantreshכn inkrεs bay 1.5-3 tεm εn i de las fכ 9-11 dez. di εstimat haf-layf fכ CJC1295 Wit DAC na 5.8-8.1 dez. Afta mכltipכl administreshכn, di avεrej IGF-I lεvεl bin de oba di beslayn lεvεl fכ te 28 dez.

di rol we de mek di hכmon dεm we de gro: 

insay animal mכdel dεm wit growth כmon (GH) dεfisiεns, CJC1295 Wit DAC dεn sho pכsitiv ifekt dεm. Fɔ mays we gɛt GHRH jin ablashɔn, animal dɛn we de gɛt wan de doz fɔ CJC1295 Wit DAC sho nɔmal bɔdi wet ɛn bɔdi lɔng ^[4] Mays dɛn we dɛn trit ɛvri 48 ɛn 72 awa bin gɛt ay bɔdi wet ɛn bɔdi lɔng pas animal dɛn we dɛn trit wit plasɛbo. pan ɔl we dɛn nɔ bin ebul fɔ du kɔmplit nɔmalizeshɔn fɔ di gro, dɛn bin sho sɔm impɔtant tin dɛn bak. Insay ɔl di tritmɛnt grup dɛn, di rilitiv slim mas ɛn di sabkyutan fat mas bin nɔmal. CJC1295 Wit DAC dεn kכz bak inkrεs pan tכtal pituitary RNA εn GH mRNA, we sho se di somatotroph sεl dεm de gro, wan rizulεt we dεn kכnfכm bay immunohistochemical imej dεm.

Aw CJC1295 Wit DAC de ajɔst wan mɔ sustayn ifɛkt pan strɔkchɔ?

Kovalεnt binding wit sεrum albumin: 

CJC-1295 inkorporet wan fכnshכnal maleimide grup na di C-tεrminus, we de alaw di sכbstans fכ kכvalεntli biεn plasma protin dεm lεk sεrum albumin ^[2] Dis kכnjugεshכn de mek CJC-1295 ebul fכ de aktv insay di bכdi, εn di tεm we i de akshכn de sכmtεm lכng pas di wan we nכ kכnjugεt pεptida dכg dεm we de kכmכt kwik kwik wan. we i tay to di sεrum albumin, CJC-1295 de fכm wan rεlatεv stebul kכmpleks, we de mek i lכng di tεm we i de akshכn na di bכdi. fכ egzampl, we di maleimide grup fכ CJC-1295 kכvalεntli biεn di fri trot pan sεrum albumin, in haf layf na di bכdi de inkrεs bכku bכku wan. dis kכnjugεshכn mεtכd na yunik bitwin pεpti dεm we de εnhans di pεrformεns εn i de lay di fawndeshכn fכ di sכstayn ifekt fכ CJC-1295 ^{[5] .}.

Fɔ mek di stebul bɛtɛ: 

tri maleimide dεrivεt dεm bin sεntez bay we dεn mכdify di hכman gכt hכmon-rilis fכktכ(hGRF), bitwin dεm CJC-1295 na tεtra-sכbstityut fכm fכ hGRF (1-29), wit di Nε-3-maleimidopropionamide dεrivεt fכ laysin we dεn ad na di C-tεrminus ^[6] .Dis strכkchכ de mek CJC-1295 dכn εnhans in vitro stεbiliti εgεst dipεptidayl pεptidaz-IV. insay di gכt hכmon sekreshכn analisis fכ kכlt rat antεriכr pituitary sεl dεm, כl di tri hכman sεrum albumin kכnjugεt dεm bin bayolojikal aktv. we dεn injεkt di maleimide dεrivεt dεm sכbkutan wan insay nכmal man Sprague Dawley rat dεm, dεn dεtekt akyu gכt hכmon sekreshכn insay di plasma. pan dεm, CJC-1295 sho 4-fol inkrεs na di εria כnda di gכt hכmon kכv kכmpεr wit hGRF (1-29) insay 2 awa. apat frכm dat, wεstεn blכt analisis fכ di plasma fכ rat dεm we dεn injεkt wit CJC-1295 sho di prεsεns fכ CJC-1295 imyun riaktiv sכbstans insay di bכnd we kכrεspכnd to sεrum albumin, we apin 15 minit afta injεkshכn εn i bin de insay di sεkyuleshכn fכ mכr dan 24 awa. dis rizulεt dεm sho se CJC-1295 na stebul εn aktv hGRF (1-29) analכg wit εkstend plasma haf-layf ^[6]..

Efεkt כf CJC-1295 pan tכtal bכdi wt (TBW; min±SE). Na di ɛnd ɔf di 5-wk tritmɛnt tɛm, di CJC/24 h grup sho kɔmplit nɔmal TBW. CJC/48 h ɛn CJC/72 h grup dɛn rich wan signifyant ay TBW kɔmpia wit di GHRHKO/pbo grup, pan ɔl we i bin stil smɔl pas di HTZ/pbo grup.

Sos:PubMed ^{[4] we dɛn pul am.}

Wetin na di klinik aplikeshɔn dɛm fɔ CJC1295 Wit DAC?

CJC1295 wit DAC kin ifektivli stimulate di sekreshכn fכ di growth כmon (GH). mכltipכl stכdi dεn sho se dis dכg kin inkrεs di avεrej plasma GH kכnsantreshכn insay hεlty big pipul dεm insay wan we we dipεnd pan dכz ^[3] . Fכ egzampl, insay wan stכdi pan hεlty pipul dεm, pipul dεm we ol bitwin 21 εn 61 ia bin gεt avεj plasma GH kכnsantreshכn inkrεs 2-10 tεm fכ 6 dez כ lכng afta dεn gεt sabkutan injεkshכn fכ CJC1295 Wit DAC. dis ifekt we de mek di hכmon dεm we de gro na di gכt de kכmכt na big minin fכ di sik pipul dεm we gεt di gכt hכmon dεm.

Fɔ pikin dɛm we nɔ gɛt bɛtɛ ɔmon fɔ gro, pan ɔl we bɔku pikin dɛn gɛt gud growth rispɔns to growth ɔmon-rilis ɔmon (GHRH), di shɔt haf layf we GHRH de liv de stɔp in klinik aplikeshɔn. as lכng-aktin GHRH analכg, CJC1295 Wit DAC kin sεlektivli kכvalεntli biεn to εndojεnik albumin, so dat i de lכng in haf-layf εn di tεm we i de akshכn. insay di stכdi we dεn du pan GHRH jin kכkכt (GHRHKO) mays, dεn fכnshכn se wan tεm evride administreshכn fכ CJC1295 Wit DAC kin mεnten di nכmal bכdi wet εn bכdi lεngth fכ mays, we sho se dis dכg gεt pכtεnshal aplikεshכn valyu fכ tritmεnt fכ di pikin gכt hכmon dεfisiεns ^[4]. .

CJC1295 wit DAC nכ kin כnli mek di gכt hכmon sekreshכn bכt i kin inkrεs di lεvεl fכ insulin lεk gכt fכktכ I. Insay klinik stכdi dεm, afta wan injεkshכn fכ CJC1295 Wit DAC, di avεrej plasma IGF-I kכnsantreshכn insay hεlty big pipul dεm inkrεs bay 1.5-3 tεm insay 9-11 dez. εn afta mכltipכl administreshכn, di avεrej IGF-I lεvεl kin de oba di beslayn fכ te 28 dez ^[4] . IGF-I gεt difrεn imכtant fysiolojikal wok dεm na di mכtalman bכdi, we inklud fכ mek di sεl dεm proliferashכn, difrεns, εn fכ liv, εn fכ rεgεl di mεtabolism, εtk.

Wetin na di pɔtɛnɛshɛl aplikeshɔn dɛm fɔ CJC1295 Wit DAC na klinik ɛn rilat fild dɛm?

Di ɔmon we de mek pɔsin gro: 

CJC1295 wit DAC kin kכntinyu fכ stimul di pituitary gland fכ sekret gכt כmon. fכ di sik pipul dεm we nכ de kכmכt na di gכt hכmon bikoz fכ difrεn rizin dεm, spεshal pikin dεm εn yכng pipul dεm, i kin bכku bכku wan fכ impruv di kכndishכn fכ gro εn divεlכpmεnt rεtardεshכn εn protεkt di ayt growth. Insay di tritmɛnt fɔ di growth ɔmon dɛfisiɛns, tradishɔnal growth ɔmon riplesmɛnt tɛrapi dɔn ajɔst sɔm rizɔlt, bɔt CJC1295 Wit DAC gɛt spɛshal bɛnifit dɛn. i kin kכvalεntli biεn to εndojεnik albumin, we de mek i lכng in haf layf εn di tεm we i de akshכn ^[4] . fכ egzampl, insay di stכdi we dεn du pan GHRH jin knockout mays, dεn fכnshכn se di de administreshכn fכ CJC-1295 tritmεnt kin mεnten di nכmal bכdi kכmכshכn εn growth fכ GHRHKO mays, inklud nכmal bכdi wet, bכdi lεngth, rilitiv sεl mas, εn sכbkutan fεt mas, εn di sem tεm i kin mek bak inkrεs pan tכtal pituitary RNA εn GH mRNA, we kכnfכm di proliferashכn fכ di growth כmon-sekret sεl dεm (Alba M, 2006).

Fɔ big pipul dɛn we nɔ gɛt bɛtɛ ɔmon fɔ gro, CJC1295 Wit DAC nɔ kin jɔs mek di bɔdi kɔmpɔzishɔn bɛtɛ, i kin mek di mɔsul dɛn bɔku, ɛn i kin ridyus di bɔdi fat bɔt i kin mek di kwaliti fɔ layf bɛtɛ. di ɔmon we de mek pɔsin gro impɔtant bak de ple impɔtant pat pan di big pɔsin in bɔdi. i de involv insay di mεtabolik rεguleshכn fכ di protin dεm, fεt dεm, εn kכbaidret dεm. Di ɔmon we de gro go mek i gɛt prɔblɛm dɛn lɛk we di bɔdi fat go bɔku, di mɔsul dɛn we de go dɔŋ, ɛn di bon dɛn we nɔ de bɔku. Di yus fɔ CJC1295 Wit DAC kin kɔrɛkt dɛn abnɔmal tin ya to sɔm mak ɛn impruv di bɔdi kɔndishɔn fɔ di sik pipul dɛn.

Anti-aging: fɔ mek pɔsin ol: 

We di ej de go ɔp, di we aw mɔtalman de mek di ɔmon we de gro de go dɔŋ smɔl smɔl, ɛn dis go mek sɔm chenj dɛn we gɛt fɔ du wit ol ol. CJC1295 Wit DAC gɛt pɔtɛnɛshɛl aplikeshɔn valyu insay anti-ɛj. I kin mek di ɔmon we de gro na di bɔdi go ɔp to sɔm mak, we kin ɛp fɔ mek di bɔdi wok we gɛt fɔ du wit ol ol nɔ de go dɔŋ. Fɔ ɛgzampul, i kin mek di bon dɛn bɔku mɔ ɛn mɔ. di כmon we de gro kin mek di כstioblast dεm wok, i kin mek di bon dεm bכku, εn i kin mek di כstioporosis nכ de; εnhans di mכsul dεm trεnk. di כmon we de gro kin mek di mכsul protin sεntez, inkrεs di mכsul mas εn trεnk; impruv di skin elasticity ɛn luster. di hכmon we de gro kin mek di skin fכm εn elastik bay we i de mek di kolagen sεntez ^{[4] .}.

Spɔt mɛrɛsin ɛn rihabiliteshɔn: 

CJC1295 Wit DAC gɛt pɔtɛnɛshɛl aplikeshɔn dɛn fɔ rihabiliteshɔn fɔ spɔt injuri ɛn fɔ impɔtant atletik pefɔmɛns. I kin mek di mɔsul dɛn ripɛnt ɛn rijeneshɔn ɛn i kin mek di wund wɛl kwik kwik wan. We atlet inju, di bɔdi nid fɔ mek di tisu we dɔn pwɛl kwik kwik wan fɔ mek i ebul fɔ ple atlet bak. di כmon we de mek di pikin gro de ple imכtant rol fכ dis prכsεs. i kin mek di sεl dεm proliferate εn difrεns, i kin mek di protin sεntez, εn i kin mek di mכsul dεm εn כda tisu dεm rεpa kwik kwik wan ^[4] . di sem tεm, CJC1295 Wit DAC kin inkrεs mכsul trεnk εn εndurance εn εnhans atletik abiliti. di ɔmon we de gro kin mek di mɔsul dɛn bɔku ɛn i kin mek di mɔsul dɛn ebul fɔ kɔntrakt, ɛn dis kin mek di atlet dɛn gɛt mɔ trɛnk ɛn ebul fɔ bia ^[4]. .

Di sik dɛn we kin mek pɔsin gɛt bɔdi: 

fכ sכm mεtabolik sik dεm lεk fכ fat εn insulin rεsistεns, CJC1295 Wit DAC kin afekt enεji mεtabolism εn fεt distribushכn εn impruv insulin sεnsitiviti bay we i de rεgεl di gכt כmon-insulin-lεk gכt fכktכ aks. Fat na wan kɔmɔn mɛtabolik sik, ɛn di we aw i kin apin kin gɛt fɔ du wit di imbalans bitwin di ɛnaji we pɔsin de it ɛn we i de it. Di ɔmon we de mek pɔsin gro kin mek di fat brok ɛn i kin mek i yuz mɔ ɛnaji, ɛn dis kin ɛp fɔ kɔntrol di bɔdi wet. di insulin rεsistεns de tכn to di dכn we di bכdi in sεnsitiviti to insulin, we de mek di bכdi shuga lεvεl go כp. di ɔmon we de mek pɔsin gro kin mek di insulin sɛnsitiviti fayn ɛn i kin mek di blɔd shuga nɔ bɔku ^{[4] .}.

fכ kכnklud, CJC1295 Wit DAC dכn sho pכsitiv ifekt in mכltipכl aspek dεm na di fil fכ gכt hכmon rεguleshכn. I gɛt impɔtant valyu nɔto jɔs fɔ trit di growth ɔmon dɛfisiɛns bɔt i gɛt bak fɔ spɔt mɛrɛsin ɛn rihabiliteshɔn ɛn anti-aging risach. Di we aw i de wok fɔ lɔng tɛm de ridyus di frɛkuɛns we dɛn de gi am, ɛn in gud sef ɛn tolɛrabiliti de gi strɔng sɔpɔt bak fɔ in klinik aplikeshɔn. Pan ɔl we i stil de na di risach stej pan sɔm fild dɛm lɛk anti-aging, di ifɛkt dɛm we dɛn dɔn ɔlrɛdi sho na infεkt fɔ pruv in yon advantej ɛn brayt aplikeshɔn prɔspɛkt dɛm na di fild fɔ layf sayɛns ɛn ɔda tin dɛm we gɛt fɔ du wit am.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Teichman SL na pɔsin we gɛt bɔku ɛkspiriɛns ɛn we gɛt pawa pan di wok dɛn we dɛn de du fɔ mɛn pipul dɛn ɛn fɔ mek mɛrɛsin. I gɛt tayt kɔnekshɔn wit bɔku institiushɔn ɛn kɔmni dɛn we pipul dɛn sabi, lɛk Ɔganayzeshɔn Kɔnsɛnt Analjɛs Inc, Teichman Drug Dev Kɔnsaltin, Wrɔklɔ Mɛdikal Yunivasiti, BEAT Bayotɛrapi Kɔp, Kɔtɛra Inc ɛn in kɔmni dɛn we gɛt fɔ du wit am Kɔtɛra, Chiasma, ARYx Tɛrapi Ink, ɛn ɔda wan dɛn bakgrɔn pan mɛdikal risach ɛn klinik prɛktis. In prɔfɛshɔnal eria dɛn de kɔba bɔku bɔku fild dɛn we inklud Kadiɔvaskyuɛl Sistɛm & Kadiɔlɔji, Jɛnɛral & Intanɛt Mɛdisin, Ɛnjinia, Ɛndokrinɔlɔji & Mɛtabolism, ɛn Famakɔlɔji & Famasi, wit wɔndaful ajɔstmɛnt ɛn kɔntribyushɔn spɛshal wan pan drɔg divɛlɔpmɛnt ɛn bayɔtɛrapi. Teichman SL de list in di rεfrεns כf saytεshכn [3].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Van Hout MC, Hearne E. Nεtnografi fכ Fem Yuz כf di Sεntetik Grכw Hכmכn CJC-1295: Puls εn Poshכn[J]. Sɔbstans Yuz & Misyuz, 2016, 51 (1): 73-84.DOI: 10.3109/10826084.2015.1082595.

[2] Timms M, Ganio K, Steel R. Wan we fɔ kɔnfɔm CJC-1295 abiuz insay ɛkwi plasma sɛmpul dɛn bay LC-MS/MS[J]. Drug Tɛsting ɛn Analysis, 2019,11(8):1248-1257.DOI:10.1002/dta.2599.

[3] Teichman S. L., Nil A, Lɔrɛns B, ɛn ɔda pipul dɛn. lכng stimulashכn fכ di gכt כmon (GH) εn insulin lεk gכt fכktכ I sekreshכn bay CJC-1295, we na wan lכng-aktin analכg fכ GH-rilis כmon, insay hεlty big pipul dεm[J]. J ɔ rnal ov Klinik Ɛndokrinɔlɔji & Mɛtabolism, 2006,91(3):799-805.DOI:10.1210/jc.2005-1536.

[4] Alba M, Fintini D, Sagazio A, ɛn ɔda pipul dɛn. wan tεm evri de administreshכn fכ CJC-1295, we na lכng-aktin gכt hכmon-rilis כmon (GHRH) analכg, de nכmal growth in di GHRH knockout maws[J]. Amɛrikan Jɔnal fɔ Fisiɔlɔji-Ɛndokrinɔlɔji ɛn Mɛtabolism, 2006,291(6):E1290-E1294.DOI:10.1152/ajpendo.00201.2006.

[5] Timms M, Ganio K, Fɔrbs G, ɛn ɔda pipul dɛn. wan imyuno polimεrayz chen riakshכn skrin fכ ditekshכn fכ CJC-1295 εn כda growth-hכmon-rilis כmon analכg dεm na εkwi plasma[J]. Drug Tɛstin ɛn Analysis, 2019,11(6):804-812.DOI:10.1002/dta.2554.

[6] Jεtε L, Lεjεr R, Tibכdכ K, εt al. di hכman gכt hכmon-rilis fכktכ (hGRF) _1-29 -albumin bayokכnjugεt dεm de aktibכt di GRF rεsεpכta na di antεriכr pituitary in rat:: Identifyin fכ CJC-1295 as lכng-lasting GRF analכg[J]. Ɛndokrinɔlɔji, 2005,146(7):3052-3058.DOI:10.1210/ɛn.2004-1286.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.